Immunology Program

The Ming Li Lab

Research

Pictured: Ming Li
Ming Li, PhD
David H. Koch Chair in Immunological Studies

The pervasive influence of the immune system on human health and disease underscores the importance of a mechanistic understanding of immune regulation under pathophysiological conditions such as cancer. Cancer immunology research in my laboratory aims to decipher the cellular and molecular basis of tumor-elicited innate and adaptive immune responses and develop mechanism-based interventions to unlock the untapped potential of the immune system for cancer therapy.

View Lab Overview

The Li Lab

Publications Highlights

X. Zhang, S. Li, I. Malik, M.H. Do, L. Ji, C. Chou, W. Shi, K.J. Capistrano, J. Zhang, T. Hsu, B.G. Nixon, K. Xu, X. Wang, A. Ballabio, L.S. Schmidt, W.M. Linehan, M.O. Li. Reprogramming Tumor-Associated Macrophages to Outcompete Cancer Cells. Nature 2023 619: 616-623. https://pubmed.ncbi.nlm.nih.gov/37380769/

C. Chou, X. Zhang, C. Krishna, B.G. Nixon, S. Dadi, K.J. Capistrano, E.R. Kansler, M. Steele, J. Han, A. Shyu, J. Zhang, E.G. Stamatiades, M. Liu, S. Li, M.H. Do, D.S. Kang, C. Chen, I.H. Wei, E.P. Pappou, M.R. Weiser, J. Garcia-Aguilar, J.J. Smith, C.S. Leslie, M.O. Li. Programme of Self-Reactive Innate-Like T Cell-Mediated Cancer Immunity. Nature 2022, 605: 139-145. https://pubmed.ncbi.nlm.nih.gov/35444279/

E.R. Kansler, S. Dadi, C. Krishna, B.G. Nixon, E.G. Stamatiades, M. Liu, F. Kuo, J. Zhang, X. Zhang, K. Capistrano, K.A. Blum, K. Weiss, R.M. Kedl, G. Cui, K. Ikuta, T.A. Chan, C.S. Leslie, A.A. Hakimi, M.O. Li. Cytotoxic Innate Lymphoid Cells Sense Cancer Cell-Expressed Interleukin-15 to Suppress Human and Murine Malignancies. Nat Immunol. 2022 23: 904-915. https://pubmed.ncbi.nlm.nih.gov/35618834/

K. Xu, N. Yin, M. Peng, E.G. Stamatiades, A. Shyu, P. Li, X. Zhang, M.H. Do, Z. Wang, K.J. Capistrano, C. Chou, A.G. Levine, A.Y. Rudensky, M.O. Li. Glycolysis Fuels Phosphoinositide 3-Kinase Signaling to Bolster T Cell Immunity. Science 2021, 371: 405-410. https://pubmed.ncbi.nlm.nih.gov/33479154/

S. Li, M. Liu, M.H. Do, C. Chou, E.G. Stamatiades, B.G. Nixon, W. Shi, X. Zhang, P. Li, S. Gao, K.J. Capistrano, H. Xu, N.V. Cheung, M.O. Li. Cancer Immunotherapy via Targeted TGF-beta Signaling Blockade in TH Cells. Nature 2020, 587: 121-125. https://pubmed.ncbi.nlm.nih.gov/33087933/

View All Publications

People

Pictured: Ming Li

Ming Li, PhD

David H. Koch Chair in Immunological Studies

  • Immunologist Ming Li studies mechanisms of immune regulation, and their relevance to diseases including cancer.
  • PhD, Columbia University
lim@mskcc.org
Email Address
646-888-2371
Office Phone

Members

Research Technician
Research Scholar
Liangliang Ji
Research Associate
Research Fellow
Ming Li
Member and Immunologist; David H. Koch Chair in Immunologic Studies #1
Peng Li, PhD
Senior Research Scientist
Senior Administrative Assistant
Xinxin Wang
Research Scholar
Research Associate
Jing Zhang
Research Associate
Michael Bivona
Research Technician
Saida Dadi, PhD
Research Fellow
Mytrang Do
Graduate Student
Ruth Franklin
Graduate Student
Myoungjoo Kim
Graduate Student
Ming Liu
Research Fellow
Chong Luo
Director, Cell Therapy, Tome Biosciences
Briana Nixon
Research Scholar
Soyoung Oh, PhD
Research Fellow
Min Peng, PhD
Research Fellow
Ahmed Toure
Research Technician
Ke Xu
Graduate Student
Na Yin, PhD
Research Fellow
Research Technician
Research Technician
Kristelle Capistrano
Senior Research Technician
Chun Chou, Research Fellow
Research Fellow
Chaucie Edwards
Research Technician
Shengyu (Sherry) Gao
Scientist, Genentech
Administrative Assistant II
Research Fellow
Ting-Wei (Eva) Hsu
Graduate Student
Lab Technician
Research Fellow
Shun Li
Research Fellow
Isha Malik
Research Technician
Senior Administrative Assistant
Research Fellow
Wei Shi, Research Scholar
Research Scholar
Amy Shyu
Engagement Manager, McKinsey and Company
Efstathios Stamatiades
Research Scholar
Xian Zhang
Senior Research Scientist
Moses Donkor
Graduate Student
Qian Ma
Research Technician
Weiming Ouyang, PhD
Research Associate

Achievements

  • Clarivate Highly Cited Researcher (2022)
  • American Association for the Advancement of Science Fellow (2021)
  • Howard Hughes Medical Institute Faculty Scholar (2016)
  • AAI-BD Biosciences Investigator Award for Outstanding Contributions to the Field of Immunology (2016)
  • Scholar, Leukemia and Lymphoma Society (2014)
  • Louise and Allston Boyer Young Investigator Award for Basic Research (2012)
  • Scholar, American Cancer Society (2012)
  • Scholar, Rita Allen Foundation (2008)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Ming Li discloses the following relationships and financial interests:

  • Amberstone Biosciences Inc.
    Equity; Professional Services and Activities
  • Flagship Pioneering
    Professional Services and Activities
  • META Pharmaceuticals Inc.
    Equity; Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures